NASDAQ:LPCN Lipocine - LPCN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.55 +0.01 (+1.98%) (As of 02/7/2023 11:59 AM ET) Add Compare Share Share Today's Range$0.53▼$0.5650-Day Range$0.39▼$0.5852-Week Range$0.36▼$1.89Volume22,838 shsAverage Volume117,614 shsMarket Capitalization$48.68 millionP/E Ratio13.75Dividend YieldN/APrice Target$4.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Lipocine MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside627.3% Upside$4.00 Price TargetShort InterestBearish1.66% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$10,217 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.13) to ($0.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.69 out of 5 starsMedical Sector832nd out of 1,027 stocksPharmaceutical Preparations Industry407th out of 500 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Lipocine has a forecasted upside of 627.3% from its current price of $0.55.Amount of Analyst CoverageLipocine has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.66% of the float of Lipocine has been sold short.Short Interest Ratio / Days to CoverLipocine has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Lipocine has recently decreased by 3.38%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldLipocine does not currently pay a dividend.Dividend GrowthLipocine does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LPCN. Previous Next 1.8 News and Social Media Coverage News SentimentLipocine has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Lipocine this week, compared to 1 article on an average week.Search Interest2 people have searched for LPCN on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lipocine insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,217.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.20% of the stock of Lipocine is held by insiders.Percentage Held by InstitutionsOnly 12.18% of the stock of Lipocine is held by institutions. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Lipocine are expected to grow in the coming year, from ($0.13) to ($0.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lipocine is 13.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Lipocine is 13.75, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 108.43.Price to Book Value per Share RatioLipocine has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lipocine (NASDAQ:LPCN) StockLipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The firm is involved in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. It offers TLANDO, an oral testosterone replacement therapy. The company was founded in 2011 and is headquartered in Salt Lake City, UT.Read More Receive LPCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter. Email Address LPCN Stock News HeadlinesFebruary 2, 2023 | americanbankingnews.comLipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.comJanuary 16, 2023 | finance.yahoo.comIs Lipocine Inc.'s (NASDAQ:LPCN) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?February 7, 2023 | Investing Trends (Ad)Solar Industry at Start of Long Bull Run?The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.January 5, 2023 | finance.yahoo.comLipocine to Present at Biotech ShowcaseDecember 19, 2022 | finance.yahoo.comLipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated CirrhosisNovember 9, 2022 | finance.yahoo.comLipocine Announces Financial Results for the Third Quarter Ended September 30, 2022November 3, 2022 | finance.yahoo.comLipocine Announces Senior Leadership Appointments to Advance its CNS-Focused PipelineOctober 11, 2022 | finance.yahoo.comLipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference - Yahoo FinanceFebruary 7, 2023 | Investing Trends (Ad)Solar Industry at Start of Long Bull Run?The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.October 11, 2022 | finance.yahoo.comLipocine to Present at H.C. Wainwright 6th Annual NASH Investor ConferenceSeptember 27, 2022 | finance.yahoo.comLipocine to Participate in the Cantor Neurology & Psychiatric ConferenceSeptember 27, 2022 | seekingalpha.comLipocine announces plans to focus on treating CNS disorders, shares rise ~5% - Seeking AlphaSeptember 26, 2022 | finance.yahoo.comLipocine To Focus On Central Nervous System Conditions; Explores Partnerships For Non-Core AssetsSeptember 26, 2022 | finance.yahoo.comLipocine Announces Strategic Realignment and Forward Focus on Treating CNS DisordersSeptember 23, 2022 | finance.yahoo.comLipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference - Yahoo FinanceSeptember 22, 2022 | finance.yahoo.comLipocine to Present at Ladenburg Thalmann 2022 Healthcare ConferenceSeptember 16, 2022 | finance.yahoo.comLipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD) - Yahoo FinanceSeptember 15, 2022 | nasdaq.comLipocine Announces Favorable Regulatory Pathway On LPCN 1154 For Post-Partum Depression - NasdaqSeptember 15, 2022 | benzinga.comLipocine (NASDAQ:LPCN) – Lipocine Announces Regulatory Pathway On Oral LPCN 1154 For Post-Partum Depressi - BenzingaSeptember 15, 2022 | finance.yahoo.comLipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD)August 10, 2022 | finance.yahoo.comLPCN: TLANDO LaunchedAugust 9, 2022 | finance.yahoo.comLipocine Inc. (NASDAQ:LPCN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?August 8, 2022 | apnews.comLipocine: Q2 Earnings SnapshotAugust 8, 2022 | benzinga.comRecap: Lipocine Q2 Earnings - BenzingaAugust 8, 2022 | streetinsider.comForm 10-Q Lipocine Inc. For: Jun 30 - StreetInsider.comAugust 8, 2022 | seekingalpha.comLipocine GAAP EPS of -$0.04 in-line, revenue of $0.5M beats by $0.24M (NASDAQ:LPCN) - Seeking AlphaAugust 8, 2022 | streetinsider.comForm 8-K Lipocine Inc. For: Aug 08 - StreetInsider.comSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LPCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter. Email Address LPCN Company Calendar Last Earnings11/09/2022Today2/07/2023Next Earnings (Estimated)3/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LPCN CUSIPN/A CIK1535955 Webwww.lipocine.com Phone(801) 994-7383Fax801-994-7388Employees13Year Founded1997Price Target and Rating Average Stock Price Forecast$4.00 High Stock Price Forecast$4.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+627.3%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)$0.04 Trailing P/E Ratio13.75 Forward P/E RatioN/A P/E GrowthN/ANet Income$-630,000.00 Net MarginsN/A Pretax Margin24.69% Return on Equity9.90% Return on Assets9.01% Debt Debt-to-Equity RatioN/A Current Ratio23.90 Quick Ratio23.90 Sales & Book Value Annual Sales$16.14 million Price / Sales3.02 Cash Flow$0.04 per share Price / Cash Flow12.51 Book Value$0.52 per share Price / Book1.06Miscellaneous Outstanding Shares88,510,000Free Float83,908,000Market Cap$48.68 million OptionableOptionable Beta0.88 Social Links Key ExecutivesMahesh V. PatelPresident, Chief Executive & Financial OfficerGeorge G NomikosChief Medical OfficerAnthony DelConteChief Medical DirectorNachiappan ChidambaramVice President-Product DevelopmentKrista FogartyChief Accounting OfficerKey CompetitorsAbeona TherapeuticsNASDAQ:ABEOCheckpoint TherapeuticsNASDAQ:CKPTNextCureNASDAQ:NXTCGain TherapeuticsNASDAQ:GANXProMIS NeurosciencesNASDAQ:PMNView All CompetitorsInsiders & InstitutionsWealth Effects LLCSold 37,000 shares on 2/2/2023Ownership: 1.332%Bailard Inc.Bought 82,957 shares on 2/2/2023Ownership: 0.094%Spyros PapapetropoulosBought 21,739 shares on 11/22/2022Total: $10,217.33 ($0.47/share)Two Sigma Investments LPSold 133,519 shares on 11/15/2022Ownership: 0.367%Two Sigma Advisers LPSold 100,000 shares on 11/15/2022Ownership: 0.237%View All Insider TransactionsView All Institutional Transactions LPCN Stock - Frequently Asked Questions What is Lipocine's stock price forecast for 2023? 0 Wall Street analysts have issued 1 year target prices for Lipocine's stock. Their LPCN share price forecasts range from $4.00 to $4.00. On average, they predict the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 641.7% from the stock's current price. View analysts price targets for LPCN or view top-rated stocks among Wall Street analysts. How have LPCN shares performed in 2023? Lipocine's stock was trading at $0.3978 at the start of the year. Since then, LPCN shares have increased by 35.6% and is now trading at $0.5393. View the best growth stocks for 2023 here. When is Lipocine's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023. View our LPCN earnings forecast. How were Lipocine's earnings last quarter? Lipocine Inc. (NASDAQ:LPCN) released its quarterly earnings results on Wednesday, November, 9th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). What other stocks do shareholders of Lipocine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lipocine investors own include Synergy Pharmaceuticals (SGYP), Flexion Therapeutics (FLXN), Trevena (TRVN), Heat Biologics (HTBX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Biocept (BIOC) and Catalyst Pharmaceuticals (CPRX). What is Lipocine's stock symbol? Lipocine trades on the NASDAQ under the ticker symbol "LPCN." Who are Lipocine's major shareholders? Lipocine's stock is owned by a number of retail and institutional investors. Top institutional investors include Wealth Effects LLC (1.33%), Bailard Inc. (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include John W Higuchi, Krista Fogarty, Mahesh V Patel, Morgan R Brown and Spyros Papapetropoulos. View institutional ownership trends. How do I buy shares of Lipocine? Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lipocine's stock price today? One share of LPCN stock can currently be purchased for approximately $0.54. How much money does Lipocine make? Lipocine (NASDAQ:LPCN) has a market capitalization of $47.73 million and generates $16.14 million in revenue each year. The specialty pharmaceutical company earns $-630,000.00 in net income (profit) each year or $0.04 on an earnings per share basis. How can I contact Lipocine? Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The official website for the company is www.lipocine.com. The specialty pharmaceutical company can be reached via phone at (801) 994-7383, via email at john.woolford@westwicke.co, or via fax at 801-994-7388. This page (NASDAQ:LPCN) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.